Immunomedics, Inc. (IMMU)
(Delayed Data from NSDQ)
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Immunomedics (IMMU) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.
Immunomedics (IMMU) Catches Eye: Stock Up 5.1%
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.
Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals
by Zacks Equity Research
Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals
Immunomedics' Progress in Phase II Cancer Study Encouraging
by Zacks Equity Research
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include GLUU, CLMT, TBBK, IMMU and HBM.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Immunomedics (IMMU) warrants investors' attention based on moves in the options market lately.
Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock
by Zacks Equity Research
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.
Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
by Joseph Lu
Immunomedics, Inc. (IMMU) stock soared in midday trading Thursday following the stop on the company's deal with Seattle Genetics (SGEN) after the lawsuit filed by Immunomedics' largest investor, venBio Select Advisor LLC, reported by The Street.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Immunomedics (IMMU) warrants investors' attention based on moves in the options market lately.
Immunomedics (IMMU) Worth a Look: Stock Climbs 7%
by Zacks Equity Research
Immunomedics, Inc. (IMMU) shares rose almost 7% in the last trading session.
Immunomedics Completes Enrollment In Cancer Drug Study
by Zacks Equity Research
Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.